MTOR and Familial prostate cancer: Thus, despite some promising results, it is evident that further investigation into the molecular mechanisms underpinning AR and PI3K-AKT-mTOR pathway crosstalk in prostate cancer is required to improve patient stratification and to discover new therapeutic approaches and predictive biomarkers that can inform future clinical trial design.